
This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by
our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact
Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

https://www.wsj.com/articles/merck-acquisition-would-test-emboldened-regulators-11655913706
Listen to article
(2 minutes)
For those in attendance at the two-day regulator workshop on strengthening antitrust enforcement in the pharma industry, the message couldn’t have been clearer: The days when megamergers could sail through without much scrutiny are over.
Then, almost as if to present a test case for antitrust officials, The Wall Street Journal reported two days later that New Jersey-based Merck & Co. was eyeing the purchase of Seattle area-biotech Seagen which is now worth just over $30 billion. The report noted that there may be other suitors and that pulling a deal off “could be tricky given the heightened risk of a regulatory challenge.’’
Continue reading your article witha WSJ membership
WSJ Membership
Customer Service
Tools & Features
Ads
More
Dow Jones Products
WSJ Membership
Customer Service
Tools & Features
Ads
More
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by
our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact
Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.

